Nanotherapies for the Treatment of Age-Related Macular Degeneration (AMD) Disease: Recent Advancements and Challenges
| Autor: | Tejashree Waghule, Gautam Singhvi, Ranendra Narayan Saha, Vamshi Krishna Rapalli, Prem Singh, Sunil Kumar Dubey, Srividya Gorantla, Arisha Mahmood |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Vascular Endothelial Growth Factor A
Cost effectiveness Biomedical Engineering Pharmaceutical Science Administration Ophthalmic 02 engineering and technology Disease Bioinformatics Macular Degeneration 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Pharmacotherapy Animals Humans Medicine Particle Size Adverse effect Patient compliance Drug Carriers business.industry General Medicine Middle Aged Macular degeneration 021001 nanoscience & nanotechnology medicine.disease eye diseases Nanostructures Posterior segment of eyeball Intravitreal Injections 030221 ophthalmology & optometry Nanocarriers 0210 nano-technology business |
| Zdroj: | Recent Patents on Drug Delivery & Formulation. 13:283-290 |
| ISSN: | 1872-2113 |
| DOI: | 10.2174/1872211314666200117095917 |
| Popis: | Age-related Macular Degeneration (AMD) is one of the common diseases affecting the posterior part of the eye, of a large population above 45 years old. Anti-Vascular Endothelial Growth Factor- A (Anti-VEGF-A) agents have been considered and approved as therapeutic agents for the treatment of AMD. Due to the large molecular weight and poor permeability through various eye membranes, VEGF-A inhibitors are given through an intravitreal injection, even though the delivery of small therapeutic molecules by topical application to the posterior part of the eye exhibits challenges in the treatment. To overcome these limitations, nanocarrier based delivery systems have been utilized to a large extent for the delivery of therapeutics. Nanocarriers system offers prodigious benefits for the delivery of therapeutics to the posterior part of the eye in both invasive and non-invasive techniques. The nano size can improve the permeation of therapeutic agent across the biological membranes. They provide protection from enzymes present at the site, targeted delivery or binding with the disease site and extend the release of therapeutic agents with prolonged retention. This leads to improved therapeutic efficacy, patient compliance, and cost effectiveness of therapy with minimum dose associated side-effects. This review has summarized various nanocarriers explored for the treatment of AMD and challenges in translation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|